Voyager Therapeutics Inc
NASDAQ:VYGR

Watchlist Manager
Voyager Therapeutics Inc Logo
Voyager Therapeutics Inc
NASDAQ:VYGR
Watchlist
Price: 4 USD 1.52% Market Closed
Market Cap: $222.4m

Net Margin

-402.4%
Current
Declining
by 338.4%
vs 3-y average of -64%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-402.4%
=
Net Income
$-126m
/
Revenue
$31.3m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-402.4%
=
Net Income
$-126m
/
Revenue
$31.3m

Peer Comparison

Country Company Market Cap Net
Margin
US
Voyager Therapeutics Inc
NASDAQ:VYGR
220.6m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
174.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.5B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.9B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 91% of companies in the United States of America
Percentile
9th
Based on 15 072 companies
9th percentile
-402.4%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Voyager Therapeutics Inc
Glance View

Market Cap
222.4m USD
Industry
Biotechnology

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 101 full-time employees. The company went IPO on 2015-11-11. Its gene therapy platforms enable it to engineer, optimize, manufacture, and deliver its adeno-associated virus (AAV)-based gene therapies. The company is identifying AAV capsids, the outer viral protein shells that enclose genetic material of a virus payload. The company has developed a AAV capsid discovery platform, Tropism Redirection of AAV by Cell Type-Specific Expression of RNA (TRACER) to facilitate the selection of AAV capsids with blood brain barrier (BBB) crossing and cell-specific transduction properties for therapeutic applications. Its gene therapy programs include treatment programs for Huntington's disease, monogenic amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and various diseases linked to GBA1 mutations, including Parkinson's disease, Lewy body dementia and Gaucher's disease. The company also focuses on tauopathies and indications in neuro-oncology.

VYGR Intrinsic Value
2.31 USD
Overvaluation 42%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-402.4%
=
Net Income
$-126m
/
Revenue
$31.3m
What is Voyager Therapeutics Inc's current Net Margin?

The current Net Margin for Voyager Therapeutics Inc is -402.4%, which is below its 3-year median of -64%.

How has Net Margin changed over time?

Over the last 3 years, Voyager Therapeutics Inc’s Net Margin has decreased from -24.2% to -402.4%. During this period, it reached a low of -402.4% on Sep 30, 2025 and a high of 52.8% on Dec 31, 2023.

Back to Top